

**AMENDMENTS TO THE CLAIMS**

This listing of the claims replaces all prior listings and versions:

1. (currently amended): A method of inducing production of antibodies against a cancer antigen, comprising the step of administering a bispecific antibody to the patient, said bispecific antibody comprising a first binding site capable of recognizing and binding a first antigen wherein said first antigen is FcγRIII and further comprising a second binding site capable of recognizing and binding a second antigen, in an amount sufficient to induce production of antibodies to said second antigen in said patient, wherein said second antigen is a cancer antigen selected from the group consisting of c-erbB-2, HMW mucin, HMW mucin II, and p-glycoprotein ~~and an antigen recognized by a monoclonal antibody produced by any of the following hybridomas: ATCC Accession Nos HB 11830, HB 11769, HB 11768, HB 10798, HB 10802, HB 8490, HB 8485, HB 8691, HB 11052, HB 10812, HB 8486, HB 10789, HB 8488, HB 8662, HB 8697, HB 10785, HB 10796, HB 10793, HB 11752, HB 10795, HB 10801, HB 11751 and HB 10794~~ and further wherein said second binding site comprises a binding site derived from a monoclonal antibody produced by a hybridoma selected from the group consisting of: HB11830, 452F2 (HB 10811), 741F8 (HB 10807), 759E3 (HB 10808), 454C11 (HB 8484), 387H9 (HB 10802), 113F1 (HB 8490), 317G5 (HB 8485, HB 8691), 34F2 (HB 11052), 650E2 (HB 10812), 35E6 (HB 11769), 266B2 (HB 8486), 106A10 (HB 10789), 260F9 (HB 8488 and HB 8662), 33F8 (HB 8697), 9C6 (HB 10785), 35E10 (HB 10796), 140A7 (HB 10798), 36H3 (HB11768), 788G6 (HB 8692), 200F9 (HB 10791), 697B3 (HB 10806), 120H7 (HB 10790), 203E2 (HB 10799), 254H9 (HB 10792), 245E7 (HB 8489), 2G3 (HB 8491), 369F10 (HB 8682), 15D3 (HB 11342), 421E8 (HB 10793), 310B7 (HB 11752), 32A1 (HB 10795), 219F3 (HB 10801), 42E7 (HB 11751), and 388D4 (HB 10794).

2. (original): The method according to claim 1, wherein said first binding site is a binding site derived from the monoclonal antibody produced from the 3G8 hybridoma.

3. (original): The method according to claim 1, wherein said second antigen is present in the patient.

4 to 7. (canceled).

8. (original): The method according to claim 1, wherein said bispecific antibody is produced by the hybrid hybridoma CRL 10197.

9 to 14. (canceled).

15. (original): The method according to claim 1, wherein said second antigen is not present in the patient upon first administration of the bispecific antibody.